Animal study · mice

SLU-PP-332 improved ejection fraction and survival in mice

Checked against the paper Animal studyPublished by PepVault

The takeaway

This mouse study is early evidence that SLU-PP-332 can protect heart function and survival in heart failure. It is not a human result.

Kind
Animal study
Studied in
Mice
Published
2024
Journal
Circulation

What they tested

The team wanted to know whether SLU-PP-332, a newly designed drug that switches on the estrogen-related receptors ERRα and ERRγ, could protect the heart in mice with heart failure.

How the study was done

A preclinical study in mice with heart failure caused by pressure overload. SLU-PP-332 was tested alongside a second, different agonist, SLU-PP-915, with gene activity, metabolite and genetic tests in mice and in lab-grown cells.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking SLU-PP-332? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

In mice with pressure overload heart failure, SLU-PP-332 and SLU-PP-915 both improved ejection fraction (the share of blood the heart pumps out with each beat), reduced fibrosis (scar-like tissue) and increased survival. Neither changed cardiac hypertrophy, the thickening of the heart muscle. In the mouse heart, the drugs switched on many genes tied to fatty acid use and mitochondria, and largely brought fat and energy-related metabolites back toward normal after 6 weeks of pressure overload. Genetic tests in mice and cells showed that ERRγ was the main receptor behind the heart protection.

What it doesn’t show

This was work in mice and cells, so it does not show what SLU-PP-332 does in people with heart failure. It tested one type of heart failure model.

The paper

Xu et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. 2024.

The compound

More studies on SLU-PP-332

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking SLU-PP-332? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo